微小RNA-206通过干扰CDK4和GAK的表达对前列腺癌细胞生长的影响

目的 探讨微小RNA-206(miR-206)对前列腺癌细胞中细胞周期蛋白依赖性激酶4(CDK4)和细胞周期素G相关蛋白激酶(GAK)表达的干扰作用及对前列腺癌细胞生长的影响.方法前列腺癌细胞株DU-145和PC-3为转染对象,转染miR-NC为对照组,转染miR-206为实验组.荧光实时定量PCR(qRT-PCR)检测CDK4和GAK mRNA的表达水平.Western blotting检测CDK4和GAK蛋白的表达水平.流式细胞术检测细胞周期分布.EdU增殖实验和集落形成实验检测细胞增殖能力.结果在DU-145和PC-3细胞株中,miR-NC组CDK4 mRNA表达量分别为1.00±0.09、1.00±0.10,GAK mRNA表达量为1.00±0.05、1.00±0.06;与之相比,两细胞株miR-206组中CDK4 mRNA表达明显下降,分别为0.36±0.18(t=6.572,P=0.001)、0.43±0.17(t=5.794,P=0.001),GAK mRNA表达量亦明显下降,分别为0.23±0.04(t=22.420,P<0.001)、0.32±0.08(t=14.500,P<0.001).Western blotting实验结果与qRT-PCR结果一致.流式细胞术检测结果显示,分别与两细胞株miR-NC组比较,转染miR-206后前列腺癌细胞在S期(23.60%±5.68%∶32.53%±4.52%,t=2.462,P=0.049;22.09%±4.35%∶30.96%±4.86%,t=2.720,P=0.035)和G2-M期(16.28%±7.12%∶26.63%±4.33%,t=2.484,P=0.048;14.60%±1.62%∶24.68%±7.13%,t=2.758,P=0.033)的细胞比例下降,在G0-G1期(60.13%±5.82%∶40.84%±5.37%,t=4.872,P=0.003;63.31%±3.27%∶44.36%±3.82%,t=7.533,P<0.001)的细胞比例升高.EdU增殖实验结果显示,转染miR-206的细胞增殖能力明显减弱(22.56±3.81∶38.90±8.51,t=3.503,P=0.013;25.12±6.42∶48.45±8.92,t=4.244,P=0.005).集落形成实验结果显示,两细胞株miR-NC组形成的集落数分别为218.66±44.59、177.35±24.49,miR-206组形成的集落数分别为125.38±32.80(t=3.370,P=0.015)、82.65±14.05(t=6.708,P=0.001),提示miR-206组细胞增殖能力降低.结论 miR-206可通过干扰CDK4和GAK的表达显著抑制前列腺癌细胞的生长,提示miR-206可能成为前列腺癌的分子靶向治疗工具.     

生存素siRNA对结肠癌细胞凋亡增殖和侵袭性的影响

目的研究siRNA表达质粒沉默Survivin基因的效率及其对大肠癌细胞株SW480凋亡、增殖和侵袭性的影响.方法构建Survivin基因的siRNA表达质粒(pRNAT/sur-siRNA),用Westeron-blot和半定量RT-PCR研究该表达质粒转染SW480后Survivin蛋白和mRNA表达的变化,流式细胞仪检测Survivin基因沉默后SW480细胞凋亡的变化,MTT法检测SW480细胞体外增值的变化细胞侵袭性实验研究SW480细胞的侵袭性变化.结果针对Survivin的siRNA的表达质粒下调大肠癌SW480细胞株Survivin蛋白和mRNA的表达水平,分别为85.0%,80.0%;pRNAT/sur-siRNA转染SW480后,SW480细胞凋亡率为16.9%;细胞增殖抑制率为37.4%,与对照组相比有显著差异(P＜0.01);细胞侵袭实验示pRNAT/sur-siRNA/SW480细胞、pRNAT/SW480、SW480细胞的细胞穿透数分别为153±66、505±65、578±98个,(P＜0.01).结论针对Siurvivin的siRNA可以显著降低Survivin的表达,从而抑制肿瘤细胞的增殖和侵袭,促进肿瘤细胞的凋亡.     

Shp2对舌癌细胞恶性生物学行为的调控作用

目的 探讨Src同源磷酸酪氨酸磷酸酶2(Shp2)在舌癌组织中的表达水平及其对Cal-27细胞增殖、转移、侵袭、凋亡等恶性生物学行为的影响.方法 采用免疫组织化学法检测舌癌组织中Shp2的表达情况;采用RNA干扰技术靶向沉默Cal-27细胞中Shp2的表达;采用噻唑蓝(MTT)法检测Cal-27细胞24、48、72、96 h的增殖活性;采用流式细胞术检测Shp2对Cal-27细胞凋亡的影响;采用蛋白质印迹(Western blot)法检测Shp2对Cal-27细胞中Bax、p53和Bcl-2蛋白表达的影响;采用Transwell小室侵袭实验和划痕实验检测Shp2对Cal-27细胞体外侵袭和迁移能力的影响.结果 舌癌组织中Shp2的阳性表达率明显高于癌旁正常组织(P﹤0.01);Shp2-siR-NA Cal-27细胞的增殖、侵袭和迁移能力均低于Cal-27细胞(P﹤0.05).与空白对照组比较,Shp2-siRNA组和阴性对照组的Cal-27细胞凋亡率均有所升高,差异均有统计学意义(P﹤0.05).Shp2-siRNA组中的p53、Bax蛋白表达水平均高于空白对照组和阴性对照组,Bcl-2蛋白表达水平低于空白对照组和阴性对照组,差异均有统计学意义(P﹤0.05).结论 Shp2在舌癌细胞中具有促癌基因的活性,可促进Cal-27细胞的增殖、迁移、侵袭,抑制其凋亡.     

miRNA141表达的调控对人前列腺癌DU145细胞恶性生物行为的影响

目的：研究microRNA-141（miR-141）表达的调控对人前列腺癌细胞系DU145细胞增殖、周期、凋亡、侵袭和迁移等恶性生物学行为的影响及其作用机制。方法：利用脂质体Lipofectamine2000将miR-141 mimics（miR-141 up组）和miR-141 inhibi‐tiors（miR-141 down 组）分别转染至人前列腺癌DU145细胞中,同时设置未转染组（Control组）和miRNA无义序列转染组（NC组）。qPCR检测转染前后各组DU145细胞中miR-141表达变化,MTT方法检测各组DU145细胞的增殖活力和对顺铂（DDP）作用敏感性变化,流式细胞术检测各组DU145细胞周期和顺铂作用下凋亡率变化,Transwell方法检测各组细胞侵袭和迁移能力的变化,Western blotting检测各组细胞中VEGF、EGFR蛋白表达量变化。结果：与Control组和NC组相比,miR-141 down组DU145细胞中miRNA-141表达水平下降为（0.18±0.08）,其细胞增殖活力显著下降而对DDP敏感性显著上升、细胞周期被阻滞于G0+G1期而细胞凋亡率显著上升至（46.67±5.86）%、细胞侵袭率和迁移率分别显著下降至（44.34±8.32）%和（57.73±6.19）%、VEGF和EGFR相对表达量分别下降至（0.47±0.06）和（0.36±0.06）（上述各指标分别P<0.05或P<0.01）。miR-141 up组DU145细胞中miR‐NA-141表达水平上升为（4.23±0.53）,其细胞增殖活力显著上升而对DDP敏感性显著下降、细胞周期提前进入S和G2期而细胞凋亡率显著下降至（18.77±4.24）%、细胞侵袭率和迁移率分别显著上升至（89.94±6.34）%和（94.44±5.84）%、VEGF和EGFR相对表达量分别上升至（0.89±0.07）和（0.73±0.06）（上述各指标分别P<0.05或P<0.01）。结论：miR-141在前列腺癌DU145细胞中发挥促癌因子作用,其下调表达能够显著抑制DU145细胞增殖活力、周期、侵袭与迁移,而促进对DDP的敏感性和细胞凋亡,其机制可能与其抑制VEGF和EGFR蛋白表达有关。     

蝎毒多肽提取物诱导前列腺癌DU-145细胞凋亡的实验研究

目的探讨蝎毒多肽提取物（PESV）诱导前列腺癌DU-145细胞凋亡的作用及机制。方法用PEsV（40μg／mL）处理DU-145细胞，采用Gimeea染色法观察凋亡细胞形态变化；采用免疫组化S-P法检测核增殖抗原Ki-67及凋亡相关基因bax和bcl-2的表达，并用病理图像分析软件进行半定量分析；TUNEL法检测凋亡细胞，并计算前列腺癌细胞增殖指数（proliferating index，PI）和凋亡指数（apoptosis index，AI）。结果PESV在体外对DU-145细胞有中度增殖抑制效应；在PESV作用下，DU-145细胞出现显著的细胞凋亡征象，凋亡指数明显增高，增殖指数降低．AI／PI明显增高（P〈0．05）。PESV处理DU-145细胞可明显提高凋亡相关基因bax表达水平，降低凋亡抑制蛋白Bcl-2表达水平，使Bel-2／Bax比值明显减小（P〈0．05）。结论PESV（40μg／mL）可以诱导细胞凋亡，而且至少是通过促进Bax、抑制Bel-2基因表达的机制诱导细胞凋亡。     

丹参酮ⅡA对乳腺癌细胞的影响及其分子机制

目的 观察丹参酮ⅡA(TanⅡA)对乳腺癌细胞增殖和凋亡的影响,并探讨其分子机制.方法 选取处于对数生长期的乳腺癌MCF-7细胞,设对照组(0μg/ml TanⅡA)和处理组(0.25、0.50、0.75μg/ml TanⅡA),处理MCF-7细胞48 h.MTT法检测各组MCF-7细胞的增殖抑制率,流式细胞术检测各组MCF-7细胞的凋亡率,Western Blot和RT-PCR分别检测各组MCF-7细胞中p53、Bcl2的蛋白和mRNA表达水平.结果 与对照组比较,不同剂量TanⅡA处理组的MCF-7细胞增殖抑制率升高(P﹤0.05),且呈剂量-时间依赖性;随着TanⅡA作用剂量的增加,MCF-7细胞的凋亡率逐渐增大,均高于对照组(P﹤0.05).与对照组比较,0.75μg/ml TanⅡA处理组的p53蛋白表达升高,Bcl2蛋白表达水平下降,差异有统计学意义(P﹤0.05);与对照组比较,0.75μg/ml TanⅡA处理组的p53 mRNA表达水平增加,Bcl2 mRNA表达水平降低,分别为对照组的4.88倍和0.42倍(P﹤0.05);0.75μg/ml TanⅡA处理组的p-AKT蛋白表达水平(0.866±0.015)低于对照组的p-AKT蛋白表达水平(1.000±0.020),差异有统计学意义(P﹤0.05).结论 TanⅡA对乳腺癌MCF-7细胞具有抑制增殖和促进凋亡的作用,其凋亡作用与p53和Bcl2蛋白的表达有关,其抗凋亡机制与p-AKT信号通路有关.     

靶向同源盒A10特异性干扰性小RNA序列的筛选及功能鉴定

 【摘要】　目的　筛选有效干扰同源盒（HOX）A10基因表达的特异性干扰性小RNA（siRNA）序列并鉴定其功能,为利用RNA干扰技术靶向HOXA10防治肿瘤提供实验依据。方法　设计合成3对针对HOXA10基因不同位点的siRNA序列,应用阳离子脂质体介导转染人肺腺癌A549细胞,采用反转录-聚合酶链反应（RT-PCR）检测HOXA10 mRNA表达,以HOXA10与β-actin灰度比值（ODR）表示相对表达水平。筛选出抑制HOXA10效果最佳的siRNA序列,应用四甲基偶氮唑盐（MTT）和流式细胞术分别检测该siRNA干扰HOXA10后对A549细胞增殖和凋亡的影响。结果　3对siRNA均能抑制HOXA10的表达,其中siRNA1抑制HOXA10 mRNA的表达最为明显,ODR为（20.190±1.698）%;siRNA1对A549细胞的增殖抑制率可达（69.793±2.092）%;siRNA转染后细胞凋亡率显著提高,siRNA1诱导A549凋亡作用最为明显,凋亡率为（29.593±2.670）%。结论　筛选出的siRNA1序列可有效沉默HOXA10基因的表达,并能有效抑制A549细胞增殖、促进其凋亡。     

siRNA靶向沉默COX-2对宫颈癌细胞VEGF、EGFR表达的影响

目的 探讨siRNA靶向沉默环氧合酶-2(COX-2)基因对宫颈癌HeLa细胞血管内皮生长因子(VEGF)和表皮生长因子受体(EGFR)表达的影响.方法 以人宫颈癌HeLa细胞为研究对象,采用COX-2 siRNA转染HeLa细胞作为转染组,以未转染的HeLa细胞作为空白对照组,以阴性对照siRNA转染HeLa细胞作为阴性对照组.逆转录聚合酶链反应(RT-PCR)检测COX-2、VEGF、EGFR基因的表达水平,蛋白质印迹法(Western blot)检测COX-2、VEGF、EGFR蛋白的表达水平,MTT法检测细胞的增殖情况,流式细胞仪检测细胞的凋亡情况,Tran-swell小室检测细胞的迁移和侵袭能力.结果 RT-PCR结果显示,转染组的COX-2、VEGF、EGFR基因表达水平均低于空白对照组和阴性对照组,差异均有统计学意义(P﹤0.05).Western blot结果显示,转染组的COX-2、VEGF、EGFR蛋白表达水平均低于空白对照组和阴性对照组,差异均有统计学意义(P﹤0.05).MTT检测结果显示,转染组的细胞增殖抑制率高于空白对照组和阴性对照组,差异均有统计学意义(P﹤0.05).流式细胞仪检测结果显示,转染组的细胞凋亡率高于空白对照组和阴性对照组,差异均有统计学意义(P﹤0.05).Transwell小室检测结果显示,转染组的细胞穿透率低于空白对照组和阴性对照组,差异均有统计学意义(P﹤0.05).结论siRNA靶向沉默COX-2基因能够抑制HeLa细胞中VEGF和EGFR的基因及蛋白表达水平,促进HeLa细胞凋亡,抑制HeLa细胞增殖,降低HeLa细胞的迁移及侵袭能力.     

蝎毒多肽提取物对前列腺癌细胞侵袭力影响的体外研究

目的:观察蝎毒多肽提取物(PESV)对前列腺癌DU-145细胞侵袭力的影响,并探讨其可能作用机制.方法:前列腺癌DU-145细胞经PESV处理后,用MTT法检测其生长与增殖的变化;Transwell小室法观察其体外侵袭能力的变化;免疫组织化学方法及逆转录聚合酶链反应(RT-PCR)法研究其基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶抑制剂-1(TIMP-1)的蛋白水平和mRNA水平表达的变化.结果:经PESV处理后,DU-145细胞的增殖受抑制.体外侵袭实验结果显示,对照组每100倍视野穿过的细胞数平均为(51.29±7.56)个,而5、10和20 μg/mL PESV作用24 h后,每100倍视野穿过的细胞数分别为(20.43±1.51)、(12.29±2.75)和(5±1.73)个,不同浓度组比较差异有统计学意义,F=38.933,P=0.000.PESV组侵袭细胞数目较对照组明显减少,P值均为0.000;免疫组化及RT-PCR结果显示,经PESV处理后,MMP-9表达下调,TIMP-1表达上调.结论:PESV抑制DU-145细胞侵袭力的作用可能与其下调MMP-9,上调TIMP-1的表达有关.     

PI3K/AKT信号通路阻断药联合小檗碱对前列腺癌DU145细胞生长的抑制作用

目的 探讨采用磷脂酰肌醇3-激酶(PI3K)抑制药——LY294002抑制磷脂酰肌醇-3-激酶/丝苏氨酸蛋白激酶(PI3K/AKT)信号通路联合小檗碱对前列腺癌DU145细胞生长的抑制作用.方法 采用MTT法检测细胞增殖情况;采用流式细胞仪检测细胞凋亡率和细胞周期分布情况;采用Western blot检测细胞中PI3K、p-AKT、cyclin D1、bcl-2、BAX蛋白表达情况.结果 随着小檗碱作用浓度的增加,DU145细胞的增殖率逐渐降低;不同浓度小檗碱与LY294002联合处理对DU145细胞增殖的抑制作用均较相同浓度小檗碱单独处理增强(P﹤0.05).与空白对照组相比,小檗碱组DU145细胞的凋亡率增高(P﹤0.05),G0/G1期细胞所占比例增高(P﹤0.05),PI3K、p-AKT、cyclin D1、bcl-2蛋白表达水平均下调(P﹤0.05),BAX蛋白表达水平上调(P﹤0.05).与小檗碱组和空白对照组相比,小檗碱+LY294002组DU145细胞的凋亡率增高(P﹤0.05),G0/G1期细胞所占比例增高(P﹤0.05),PI3K、p-AKT、cyclin D1、bcl-2蛋白表达水平均下调(P﹤0.05),BAX蛋白表达水平上调(P﹤0.05).结论 小檗碱能够抑制DU145细胞增殖,并促进细胞凋亡和细胞周期阻滞,采用LY294002阻断PI3K/AKT信号通路能够明显增强小檗碱对前列腺癌DU145细胞生长的抑制作用.     

Genistein synergizes with RNA interference inhibiting survivin for inducing DU-145 of prostate cancer cells to apoptosis

To further investigate the effect of a combination of genistein with survivin of RNA interference on the proliferation and apoptosis of DU-145 cells, the effect of genistein on the proliferation of DU-145 cells was detected by the MTT method and cytometry, and the apoptosis of cells was observed with fluorescence microscopy. In order to test combined genistein with transfection of small interfering RNA (siRNA) against survivin, a survivin siRNA plasmid was constructed and transfected into DU-145 cells. Genistein inhibited proliferation and induced apoptosis of cancerous DU-145 and Hela cells, whereas genistein had minimal effects for normal L-O2 cells. The stable transfected cell lines of DU-145, knockdown survivin by siRNA, displayed stronger apoptotic than untransfected DU-145, the transfected cell of DU-145 treated with genistein demonstrated the inhibition of proliferation and induction of apoptosis significantly; it showed genistein synergistic effect with RNAi in survivin for inhibition of prostate cancer cells.     

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA

Introduction

Vascular endothelial growth factor (VEGF) regulates several cell functions including; proliferation, differentiation, permeability, vascular tone, and the production of vasoactive molecules. The purpose of this study was to evaluate the potency of specific short-interfering RNA (siRNA) to suppress human VEGF expression by siRNA and investigate the effects of VEGF down-regulation on the cell proliferation and apoptosis of the human prostate cancer cell lines DU-145.

Methods

Transfection was performed using X-tremeGENE siRNA transfection reagent. At different time intervals, transfected cells were harvested and total RNA was extracted for RT-PCR. The VEGF content in supernatants were measured by ELISA. Inhibition of cell growth by hVEGF-siRNA was measured by using cell proliferation ELISA BrdU assay. Apoptotic cells were evaluated by using annexin-V-FITC apoptotic detection method.

Results

Transfection of hVEGF-siRNA resulted in statistically significant inhibition of hVEGF-mRNA that in turn caused a marked reduction in the expression of hVEGF. The cell growth was assessed every 24?h for 4?days after siRNA treatment resulted in a marked inhibition of cell proliferation as compared to scramble siRNA. The results of apoptosis showed that approximately 15?% of the cells treated with control-siRNA manifested evident apoptotic changes after 24?hpt, whereas DU-145 cells treated with hVEGF-siRNA significantly were positive, that is to say, 53?% at 72?hpt 23.9?±?2.78?% (P?<?0.001) and 13?±?1.57?% at 96?hpt.

Conclusion

Our findings indicate that siRNA are effective in eliciting the RNAi pathway in cancerous cells and that specific siRNA efficiently down-regulate VEGF expression. They could decrease VEGF production and induce apoptosis, which may also be linked to the inhibition of cancerous cell proliferation. Therefore, it can be concluded that siRNA-mediated suppression of VEGF represents a powerful tool against prostate cancer cell proliferation. VEGF down-regulation exerts a direct anti-apoptotic function in the DU-145 cell lines and promises the development of drugs for cancer therapy.     

Livin mediates tumor cell invasion in the DU-145 cell line via NF-κB

Livin is a member of the family of inhibitors of apoptosis proteins (IAPs) and tumor cell invasion is a general property of multiple IAPs. Livin is highly expressed in prostate cancer (PCa) tissues. Livin overexpressing cells are more resistant to apoptotic stimuli than normal cells. Thus, aberrantly increased cell survival is an invariable requirement of metastasis. In this study, we investigated whether livin signaling affects metastasis by transfecting siRNA targeting livin into the DU-145 prostate cancer cell line to confirm the anti-invasion effect and blockade of the livin gene. We found that livin knockdown inhibited DU-145 prostate carcinoma cell invasion. We investigated how livin promotes tumor cell invasion, and found that livin induction of fibronectin contributed to tumor cell invasion. In addition, we found that livin induction of fibronectin regulates tumor cell invasion via nuclear factor κB (NF-κB) signaling. These data showed that livin, as a gene directly promoting metastasis, can be useful for therapeutic intervention against advanced and disseminated PCa.     

AKT3 promotes prostate cancer proliferation cells through regulation of Akt,B-Raf & TSC1/TSC2

The qRT-PCR analysis of 139 clinical samples and analysis of 150 on-line database clinical samples indicated that AKT3 mRNA expression level was elevated in primary prostate tumors. Immunohistochemical staining of 65 clinical samples revealed that AKT3 protein expression was higher in prostate tumors of stage I, II, III as compared to nearby normal tissues. Plasmid overexpression of AKT3 promoted cell proliferation of LNCaP, PC-3, DU-145, and CA-HPV-10 human prostate cancer (PCa) cells, while knockdown of AKT3 by siRNA reduced cell proliferation. Overexpression of AKT3 increased the protein expression of total AKT, phospho-AKT S473, phospho-AKT T308, B-Raf, c-Myc, Skp2, cyclin E, GSK3β, phospho-GSK3β S9, phospho-mTOR S2448, and phospho-p70S6K T421/S424, but decreased TSC1 (tuberous sclerosis 1) and TSC2 (tuberous Sclerosis Complex 2) proteins in PC-3 PCa cells. Overexpression of AKT3 also increased protein abundance of phospho-AKT S473, phospho-AKT T308, and B-Raf but decreased expression of TSC1 and TSC2 proteins in LNCaP, DU-145, and CA-HPV-10 PCa cells. Oncomine datasets analysis suggested that AKT3 mRNA level was positively correlated to BRAF. Knockdown of AKT3 in DU-145 cells with siRNA increased the sensitivity of DU-145 cells to B-Raf inhibitor treatment. Knockdown of TSC1 or TSC2 promoted the proliferation of PCa cells. Our observations implied that AKT3 may be a potential therapeutic target for PCa treatment.     

Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells

The N-myc downstream regulated gene 1 (NDRG1) has been identified as a metastasis-suppressor gene in prostate cancer (PCa). Compounds targeting PCa cells deficient in NDRG1 could potentially decrease invasion/metastasis of PCa. A cell based screening strategy was employed to identify small molecules that selectively target NDRG1 deficient PCa cells. DU-145 PCa cells rendered deficient in NDRG1 expression by a lentiviral shRNA-mediated knockdown strategy were used in the primary screen. Compounds filtered from the primary screen were further validated through proliferation and clonogenic survival assays in parental and NDRG1 knockdown PCa cells. Screening of 3360 compounds revealed irinotecan and cetrimonium bromide (CTAB) as compounds that exhibited synthetic lethality against NDRG1 deficient PCa cells. A three-dimensional (3-D) invasion assay was utilized to test the ability of CTAB to inhibit invasion of DU-145 cells. CTAB was found to remarkably decrease invasion of DU-145 cells in collagen matrix. Our results suggest that CTAB and irinotecan could be further explored for their potential clinical benefit in patients with NDRG1 deficient PCa.     

过表达miR-141-3p通过靶向下调PTEN并激活PI3K/Akt信号通路促进卵巢癌A2780 细胞的恶性生物学行为

[摘要] 目的：探讨miR-141-3p 通过靶向PTEN并调控PI3K/Akt 通路对卵巢癌细胞增殖、侵袭和凋亡的影响。方法：收集2014 年4 月至2017 年10 月河南省人民医院妇产科收治的资料完整的28 例卵巢癌患者肿瘤组织和相应的癌旁组织,采用qPCR检测卵巢癌组织和细胞系中miR-141-3p 的表达水平,双荧光素酶报告基因实验验证miR-141-3p 和PTEN的靶向关系;过表达或敲降miR-141 及PTEN基因后,采用CCK-8、Transwell 和Annexin V-FITC/PI 双染流式术检测卵巢癌A2780 细胞增殖、侵袭和凋亡水平,WB实验进一步检测miR-141-3p 对PTEN-PI3K/Akt 信号通路的调控作用。结果：miR-141-3p 在卵巢癌组织和细胞系中高表达（P<0.05 或P<0.01）。双荧光素酶报告基因证实miR-141-3p 靶向作用于PTEN并下调其表达水平（P<0.01）。与对照组相比,敲降miR-141-3p 后A2780 细胞的增殖受到显著抑制（48 h 时,0.36±0.04 vs 0.82±0.06,P<0.05）、侵袭能力明显降低[穿膜细胞数（45.14±7.88）vs（215.32±16.04）个,P<0.01]、细胞凋亡率显著升高[ （9.29±0.65）% vs（1.85±0.26）%,P<0.01]。过表达PTEN显著抑制了A2780 细胞中p-Akt 的表达（均P<0.01）、抑制细胞增殖和侵袭能力（均P<0.01）而明显促进细胞凋亡（均P<0.01）,在过表达PTEN的同时过表达miR-141-3p 或添加IGF-1 后可逆转上述的变化。结论：miR-141-3p 能够促进A2780 细胞增殖、侵袭和诱导凋亡,其机制可能与靶向调控PTEN并激活PI3K/Akt通路有关。     

miR-613通过下调Wnt/β-catenin信号通路活性抑制前列腺癌细胞的增殖与侵袭

目的:研究miR-613在人前列腺癌组织中的表达情况,探讨miR-613是否通过下调Wnt信号通路活性抑制前列腺癌细胞系细胞的增殖和侵袭能力。方法:收集临床前列腺癌组织及配对癌旁组织20例,通过实时荧光定量PCR(RT-qPCR)检测各组组织中miR-613的表达情况。进一步在细胞实验中,通过转染miR-613 mimic和miR-NC至离体培养的PC-3、DU-145细胞中,随后,采用MTT法、平板克隆实验检测细胞增殖和Matrigel侵袭实验测定前列腺癌细胞的侵袭情况,采用荧光素酶分析方法评估Wnt信号通路活性变化,采用实时荧光定量PCR(RT-qPCR)检测Wnt/β-catenin信号通路下游靶基因的转录(包括Cyclin D1和c-Myc),WB法检测细胞中β-catenin、c-Myc和Cyclin D1的表达量。结果:相比配对癌旁组织,miR-613在前列腺癌组织中的表达降低(P<0.01);在体外细胞实验中,相比于miR-NC组,转染miR-613 mimic后,PC-3、DU-145细胞增殖能力下降(P<0.05),PC-3、DU-145细胞的迁移侵袭能力下降(P<0.01);miR-613的过表达显著降低Wnt信号通路活性、β-catenin蛋白表达及Wnt信号下游靶基因Cyclin D1和c-Myc的转录及蛋白表达。结论:miR-613通过抑制Wnt/β-catenin信号通路来影响前列腺癌细胞的增殖与侵袭,为前列腺癌的潜在治疗靶点之一。     

霞草苷Ⅱ对前列腺癌细胞侵袭力的影响

 目的观察霞草苷Ⅱ对前列腺癌DU145细胞侵袭力的影响，并探讨其可能的作用机制.方法前列腺癌DU145细胞经霞草苷Ⅱ处理后，用四甲基偶氮唑蓝法检测其生长与增殖的变化；细胞侵袭小室法观察其体外侵袭能力的变化；免疫细胞化学方法研究其基质金属蛋白酶-2（MMP-2）、CXC 趋化因子受体4（CXCR4）的表达变化.结果经霞草苷Ⅱ处理后，DU145细胞的增殖受抑制；体外侵袭实验结果显示，对照组每100倍视野穿过的细胞数平均为180.3个±14.6个，而0.25、0.5、1 μg/ml 霞草苷Ⅱ作用24 h后，每100倍视野穿过的细胞数分别为100.4个±1.5个、80.2个±2.7个和60.1个±5.3个，比对照组明显减少，（P＜0.05）；免疫细胞化学显示，经霞草苷Ⅱ处理后，MMP-2表达下调，CXCR4表达下调.结论霞草苷Ⅱ抑制DU145细胞侵袭力的作用可能与其下调MMP-2的表达有关；霞草苷Ⅱ可能通过下调DU145细胞CXCR4的表达从而抑制癌细胞向骨转移。     

过表达RFX1 对胶质瘤细胞增殖和侵袭的影响

目的:探讨过表达调节因子X1 基因（regulatory factor X1,RFX1）对神经胶质瘤细胞株F98 细胞增殖和侵袭能力的影响及其作用机制。方法：用慢病毒转染法将RFX1 转染到F98 细胞,构建过表达RFX1 的F98 细胞株（F98-RFX1 组）,同时设立空质粒对照组（F98-Vector 组）和正常培养组（F98 组）。用计数法观察过表达RFX1 对各组F98 细胞增殖的影响,用AnnexinV/PI 染色法流式细胞术检测过表达RFX1 对F98 细胞凋亡的影响,用Transwell 小室法检测过表达RFX1 对F98 细胞侵袭能力的影响。结果：成功建立过表达RFX1 胶质瘤F98 细胞株。过表达RFX1 组胶质瘤F98 细胞的增殖能力显著低于F98 组[48 h: （12.08±2.17）×104/ml vs（23.67±4.51）×104/ml,P<0.05]和F98-Vector 组[96 h: （8.17±0.31）×104/ml vs（18.58±1.18）×104/ml;P<0.05];过表达RFX1 组细胞的凋亡水平明显上升[ （21.89±2.33）% vs（3.38±1.39）%、（10.42±1.83）%,P<0.05];过表达RFX1 组细胞侵袭能力显著下降[ （33.3±7.99）vs（56.5±13.9）、（60.6±11.8）个,P<0.01]。结论：RFX1 可以调控增殖和侵袭相关基因的表达,进而抑制胶质瘤细胞的增殖和侵袭能力、促进细胞凋亡。